The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients

Table 3

Comparison of parameters between responder and nonresponder groups at treatment of CAMR.

Clinical parameters	Responder (𝑛=12)	Nonresponder (𝑛=6)	𝑃 value
Age (years)	44.0±7.0	44.3±7.9	0.928
Male gender, 𝑛 (%)	8 (67)	5 (83)	0.615
BMI (Kg/m^2)	24.0±3.2	24.9±1.8	0.518
Multitransplant History, 𝑛 (%)	1.0±0.0	1.3±0.5	0.175
Previous acute rejection, 𝑛 (%)	0.5±0.7	0.7±0.8	0.650
Serum Cr (mg/dL)	2.3±0.7	2.4±1.3	0.809
MDRD eGFR (mL/min//1.73 m^2)	34.2±14.3	39.0±20.3	0.568
Proteinuira (g/day)	2.8±2.8	7.0±3.5	0.015
Time posttransplant; before CAMR diagnosis, month	106.1±65.6	67.3±46.8	0.217
Time posttreatment, month	13.9±7.8	14.6±12.6	0.889
HLA-DSA, MFI*			0.629
Strong, 𝑛 (%)	1 (10)	0 (0)
Moderate, 𝑛 (%)	1 (10)	2 (50)
Weak, 𝑛 (%)	2 (20)	0 (0)
Negative, 𝑛 (%)	6 (60)	2 (50)
Histologic parameters
Transplant glomerulopathy	1.75±1.5	1.8±1.6	0.953
PTCBMM (+/−)	7/5	3/2	0.951
Peritubular capillaritis	1.9±1.3	1.8±1.1	0.864
IF/TA	1.4±0.8	1.5±0.5	0.821
C4d in PTC	2.25±1.4	2.8±0.8	0.436

CAMR: chronic antibody mediate rejection; BMI: body mass index; Cr: creatinine; MDRD eGFR: estimated GFR using the Modification of Diet in Renal Disease Study equation; HLA-DSA: donor specific anti-HLA antibody; PTC: peritubular capillary; BMM: basement membrane multilayering.
*16 out of 18 subjects take HLA-DSA and 14 had available data.